ZOMETA® Safety & Tolerability - Dental Health: Osteonecros Is Of The Jaw (ONJ)

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Safety & Tolerability: Dental Health

ONJ is uncommon, may be prevented, and can be managed

The causes of osteonecrosis of the jaw (ONJ) are not well understood
ONJ has been reported in patients, predominantly those with cancer, receiving treatment with bisphosphonates, including ZOMETA¹
- — Many of these patients were also receiving chemotherapy and corticosteroids
- — The majority of reported cases has been associated with dental procedures, such as tooth extraction
- — Many had signs of local infection, including osteomyelitis
<1% of patients receiving ZOMETA have been reported to experience ONJ in a retrospective review²
- — In Novartis clinical trials, the frequency of ONJ reports was also <1%³

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.